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Abstract
Background: This study was performed to evaluate the impact of baseline characteristics and treatment methods
on the outcome of sporadic renal angiomyolipoma (AML).
Methods: This was a pooled analysis of individual data of 441 patients with AML retrieved from 58 studies and 3
institutional series.
Results: Ninety-three patients underwent nephrectomy, 163 partial nephrectomy/enucleation, 128 embolisation,
19 cryoablation, 6 radiofrequency ablation, and 32 conservative treatment. Their mean follow-up period was
44.5 months. Patients who experienced major bleeding at presentation had significantly larger tumours than
did those without bleeding (mean diameter, 10.1 vs. 5.9 cm, respectively; p < 0.0001). A total of 9.4 % and
26.4 % of bleeding tumours had a diameter of <4 and <6 cm, respectively. A tumour diameter of ≥8.0 cm
(hazard ratio, 2.07; 95 % confidence interval, 1.20–4.77) and the treatment method (p = 0.001) were independent
predictors of re-intervention. The risk of re-intervention was significantly higher after embolisation, particularly
for large tumours (5-year rate of freedom from re-intervention: diameter of ≥8.0 cm, 49.2 %; diameter of <8.0 cm,
74.8 %; p = 0.018). Conservatively treated AMLs had a mean baseline diameter of 3.2 ± 2.7 cm; after 41 months, their
mean diameter was 3.7 ± 3.1 cm (p = 0.109).
Conclusions: The prevalence of major bleeding is high in sporadic AMLs with a diameter of >6 cm. These
results suggest that conservative treatment can be considered in AMLs of <6 cm in diameter. Among current
treatment methods, embolisation was associated with a significantly higher risk of re-intervention. Further studies
are needed to define risk factors for bleeding and assess the relative benefits of different treatment modalities.
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Background
Renal angiomyolipomas (AMLs) are frequent benign
renal tumours composed of fat cells, smooth muscle
cells, and blood vessels [1–3]. These tumours belong to
a family of perivascular epithelioid cell tumours [4].
AMLs occur sporadically in 80 % of cases, whilst the
remaining cases are associated with various genetic dis-
orders [2]. The incidence of AMLs in the general popu-
lation is 0.4 % [5], but this tumour has been reported in
5.7 % to 6.9 % of partially resected, preoperatively pre-
sumed cases of renal carcinoma [6, 7]. The most severe
complication related to renal AML is retroperitoneal
bleeding, which has been reported in 15 % of patients
[2] and may lead to shock in 20 % to 30 % of these
patients [8, 9].
According to the current guidelines of the European
Association of Urology [10], the primary indications for
treatment of renal AML are the presence of symptoms
or suspected malignancy. Biopsy may guide the treat-
ment decisions for lesions with unusual growth and
imaging characteristics [3]. The Level C recommenda-
tions for prophylactic intervention include large AMLs,
women of childbearing age, and patients for whom
follow-up or access to emergency care may be inad-
equate [10]. The treatment threshold for AML tumours
with a diameter of ≥4 cm has recently been disputed.
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Indeed, a recent study showed that treating all AMLs
of >4 cm may lead to an over-treatment rate of 65 % [11].
Additionally, the optimal treatment method for bleeding
tumours has not yet been defined [2, 11–14]. The aim of
this study was to evaluate the impact of baseline charac-
teristics, particularly tumour diameter, and treatment
methods on the outcome of sporadic renal AML.
Methods
A literature search of PubMed and Scopus was per-
formed in March 2014 using the key words ‘renal’ and
‘angiomyolipoma’. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) cri-
teria were followed [15, 16]. Adult patients who received
any conservative or invasive treatment for renal AML
were included in the analysis. Articles reporting on pa-
tients with tuberous sclerosis complex or epithelioid
AML were excluded. Only articles written in the English
language were included in this analysis. Two of the au-
thors individually reviewed the abstracts of the retrieved
citations to select relevant series. Data from each series
were independently extracted by the two authors and
subsequently cross-checked. This literature search iden-
tified a number of small studies with heterogeneous
treatment strategies and a lack of treatment-specific
data on survival and freedom from re-intervention,
which prevented the performance of an aggregate
survival meta-analysis. Because of these limitations, a
pooled analysis of individual patient data was performed.
Retrieved articles were reviewed for any data at the
individual level that provided information regarding sex,
symptoms, indications for invasive or conservative treat-
ment, type of treatment, freedom from re-intervention,
and survival. The definition criterion for major bleed-
ing was any sign of retroperitoneal bleeding on im-
aging examination.
Authors of case series were asked to provide these
data in a dedicated Excel spreadsheet. After permission
was granted by the Oulu University Hospital’s medical
director, data on patients treated at the Oulu University
Hospital were retrieved from the electronic records and
included in the present analysis. The study was con-
ducted according to the principles of the Helsinki
Declaration. For this retrospective chart review, no writ-
ten informed consent for participation in the study was
obtained from participants.
Statistical analysis
Data were analysed at the individual patient level using
SPSS statistical software, version 22.0 (IBM Corp.,
Armonk, NY, USA). Nominal variables are summarised
as counts and percentages, whereas continuous variables
are reported as means and standard deviations. Univari-
ate analysis was performed using the Kruskal–Wallis,
Mann–Whitney, Wilcoxon, and Fisher exact tests, as
appropriate. Freedom from re-intervention and survival
were estimated using the Kaplan–Meier method. The
impact of different baseline characteristics and operative
variables on late outcomes was evaluated using the log-
rank test and the Cox proportional hazards method.
Tumour size was first included in the multivariate ana-
lysis as a continuous variable and then dichotomised
according to incremental threshold values from 4.0 to
10.0 cm, respectively. A p-value of <0.05 was considered
statistically significant.
Results
Fifty-eight studies met the inclusion criteria and were
suitable for inclusion in the present analysis (Fig. 1).
Individual patient data were obtained from the authors
of two studies [17, 18] and from the Oulu University
Hospital (7 patients). In overall, this dataset included 441
patients with sporadic renal AML who were the subjects
of this analysis. Patient characteristics and their outcomes
are summarised in Table 1. Ninety-three patients under-
went nephrectomy, 163 partial nephrectomy or enucle-
ation, 128 embolisation, 19 cryoablation, 6 radiofrequency
ablation, and 32 conservative treatment (Table 1). Their
mean follow-up period was 44.5 ± 35.8 months.
Patients presenting with major retroperitoneal bleed-
ing (54 of 441 patients) had significantly larger tumours
than did patients without bleeding (mean maximal
tumour diameter, 10.1 ± 5.9 vs. 5.9 ± 4.7 cm, respectively;
p < 0.0001) (Fig. 2). Among the bleeding tumours, 5 of
54 (9.4 %) and 14 of 54 (26.4 %) had maximal diameters
of <4 and <6 cm, respectively.
A Cox proportional hazards model including sex
(p = 0.29), age (p = 0.38), tumour size (p = 0.24), pres-
ence of major bleeding (p = 0.86), and treatment mo-
dality (p = 0.003) showed that the treatment method was
the only independent predictor of re-intervention. When
the baseline tumour diameter was dichotomised with an
8.0-cm cutoff, the regression analysis showed that the
treatment modality (p = 0.001) (Fig. 3) and a baseline
tumour diameter of ≥8.0 cm (p = 0.013; hazard ratio [HR],
2.07; 95 % confidence interval [95 % CI], 1.20–4.77) were
independent predictors of re-intervention. The risk of re-
intervention was particularly evident in patients who had
undergone embolisation (Fig. 3). Because of this, further
analyses were performed only in the subset of patients
who underwent embolisation treatment.
Among 128 patients who underwent embolisation, a
Cox proportional hazards model including age, sex, base-
line tumour diameter, major bleeding, and tumour diam-
eter showed that only a tumour diameter of ≥8.0 cm was
an independent predictor of re-intervention (p = 0.017;
HR, 2.36; 95 % CI, 1.17–4.79). The 5-year actuarial esti-
mate of freedom from re-intervention after embolisation
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in patients with a tumour diameter of ≥8.0 cm was 49.2 %,
whereas it was 74.8 % for patients with smaller tumours
(log-rank test, p = 0.013).
Among the 32 patients who were treated conserva-
tively, the mean initial diameter was 3.2 ± 2.7 cm
(range, 1.5–14.0 cm), whereas it was 3.7 ± 3.1 cm
(range, 1.5–14.0 cm) at the end of the mean follow-up
period (41 ± 38 months) (Wilcoxon test, p = 0.109). Only 3
of these patients presenting with tumour diameters of 2.5,
4.0, and 7.0 cm demonstrated tumour growth to 6.5, 7.8,
and 9.0 cm, respectively. The latter tumours were still
treated conservatively at the last follow-up.
Fig. 1 Literature search flow chart








No. of patients 441 32 19 128 6 163 93
Age (years) 51.5 ± 14.5 53.2 ± 15.0 53.6 ± 14.8 47.9 ± 14.7 60.4 ± 6.9 52.9 ± 13.7 52.4 ± 14.9 0.020
Females 353 (80.4) 24 (75.0) 18 (94.7) 103 (80.5) 5 (80) 129 (79.6) 74 (79.6) 0.494
Imaging method <0.0001
US 9 (9.4) 3 (9.4) 0 2 (1.6) 0 2 (1.2) 2 (2.2)
CT 411 (93.6) 26 (81.3) 8 (42.1) 125 (97.7) 6 (100) 160 (98.2) 86 (94.5)
MRI 8 (1.8) 3 (9.4) 0 1 (0.8) 0 1 (0.6) 3 (3.3)
CT/MRI 11 (2.5) 0 11 (57.9) 0 0 0 0
Tumour diameter (cm) 6.5 ± 5.0 4.4 ± 5.1 2.6 ± 1.6 9.1 ± 4.8 3.9 ± 2.5 4.7 ± 4.1 7.6 ± 6.0 <0.0001
Bleeding 54 (12.2) 4 (12.5) 0 32 (25.0) 0 7 (4.3) 10 (10.8) <0.0001
3-year survival 97.9 % 100 % 94.7 % 100 % 100 % 95.6 % 98.4 % 0.037
Reintervention 41 (9.4) 1 (3.1) 0 38 (29.7) 0 2 (1.2) 0 <0.0001
Surgery 18 (4.1) 0 0 17 (13.3) 0 0 0 <0.0001
3-year freedom from
reintervention
87.8 % 96.9 % 100 % 63.5 % 100 % 98.2 % 100 % <0.0001
Data were obtained from the overall series, based on treatment strategy. Nominal variables are reported as counts and proportions; continuous variable are
reported as mean and standard deviation
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Discussion
The treatment strategy for renal AMLs is based mainly
on evidence acquired during the 1980s [8]. Because
major bleeding is the most severe complication of AML,
prophylactic treatment may be indicated to avoid this
haemorrhagic event. For many years, the threshold
diameter for prophylactic treatment has been 4 cm [8];
however, this threshold has recently been disputed
[11, 19]. Indeed, the diagnostic methods for AMLs
have improved significantly during recent years, and
the indication and efficacy of invasive treatment strat-
egies for AML should be re-evaluated in light of
Fig. 2 Box plot showing impact of baseline tumour size on severe bleeding. Fifty-four of 441 patients had severe bleeding at presentation (p < 0.0001)
Fig. 3 Cox proportional hazards model for repeat intervention. The model was created according to different treatment strategies and adjusted
for tumour diameter, presence of bleeding, age, and sex. The freedom from re-intervention curves after radiofrequency ablation and nephrectomy
are behind the cryoablation curve in the figure
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recent studies. We performed a literature review covering
the era of modern diagnostic modalities to obtain detailed
patient data on the efficacy of the current treatment strat-
egies. Most of the published data were heterogeneous and
presented significant biases. Therefore, we proceeded with
a pooled analysis of all individual patient data available in
the literature and included data from two patient series
[17, 18] along with patient data from the Oulu University
Hospital, Finland.
The present analysis showed that the risk of bleeding
is associated with a large tumour diameter. Although
even small AMLs are known to bleed, only 10 % of
bleeding tumours in our analysis were below the
traditional prophylactic treatment threshold of 4 cm. In
fact, among bleeding tumours, 5 of 54 (9.4 %) and 14 of
54 (26.4 %) were <4 and <6 cm in diameter, respectively.
This suggests that a diameter cutoff for treatment
could be appropriately set at >6 cm. Indeed, a recent
study suggested that only 34 % of patients with tu-
mours of ≥4 cm required intervention [11]. Moreover,
67 % of symptomatic patients were managed with ac-
tive surveillance and without late intervention [11].
Minimal or no growth of sporadic AMLs was simi-
larly observed in earlier studies [8, 19, 20].
The prediction of severe bleeding events associated
with AML is an important clinical issue and may dictate
the prophylactic treatment strategy. A number of studies
have suggested that the risk of bleeding is related to the
vascularity and size of the tumour [21–23]. Rimon et al.
[21] concluded that large (>4 cm) AMLs with minimal
vascularity are less likely to bleed and that a grading sys-
tem, based on tumour vascularity determined using
digital subtraction angiography, may help to select pa-
tients needing embolisation. AMLs with a dominant
large feeding vessel may be optimal for embolisation.
Although several studies [12, 24–26] have shown ex-
cellent outcomes with different treatment modalities, the
present results suggest suboptimal outcomes after AML
embolisation. In the past, embolisation was the treat-
ment of choice for AMLs [19] probably because analyses
of different treatment modalities have shown that em-
bolisation is effective for bleeding tumours [19]. Preser-
vation of the renal parenchyma [27, 28], effective
occlusion of bleeding vessels [26], and surgery preven-
tion [2] are considered the main benefits of embolisa-
tion. However, in our study, the 3-year rate of freedom
from re-intervention after embolisation was 63.5 %,
whereas it approached 100 % for all other treatment mo-
dalities. Embolisation was performed in 128 tumours,
30.5 % of which were asymptomatic and 25.0 % of which
were bleeding. Tumours treated by embolisation also
had the largest mean diameter (9.1 ± 4.8 cm). Remark-
ably, only the treatment modality was associated with a
risk of re-intervention, consistent with the results of
other series [12, 19, 24–26, 28]. We observed that the risk
of re-intervention was lower if embolisation was per-
formed for bleeding tumours with a diameter of <8 cm.
Embolisation is less effective than partial nephrectomy for
tumours of >8 cm likely because of their high vascularity,
making embolisation of these large tumours more com-
plex and less efficacious.
Although the number of patients who underwent inva-
sive methods in our included studies was rather small,
no re-interventions after either cryoablation or radiofre-
quency ablation were reported (Table 1). Castle et al.
[29] reported no recurrence after radiofrequency abla-
tion of AMLs with a mean diameter of 2.6 cm. It has
been suggested that radiofrequency ablation may also be
a valid treatment option for larger tumours [30]. How-
ever, post-treatment retroperitoneal bleeding due to frac-
ture of the tumour mass during the procedure may be a
significant concern if larger AMLs are treated with
cryoablation [31, 32].
The data presented herein support the current strategy
for surveillance in asymptomatic patients. Based on our
results and those presented earlier [11], aggressive use of
prophylactic treatment should be avoided to prevent
over-treatment. Based on the present data and a prior
study [33], surgery provides good results for larger
bleeding AMLs. A 3.4 % recurrence rate among surgi-
cally treated patients was observed during a median
follow-up of 8 years [33]. However, the risk of major
postsurgical complications (range, 7 % to 12 %) [33, 34]
is far higher than that of severe adverse events after
embolisation [12]. Elective surgical treatment after
emergency embolisation performed to stop bleeding
may be the treatment of choice for patients not at
high risk for major surgery. Additional data are needed
to assess the efficacy and durability of radiofrequency
ablation and cryoablation in this setting. Prospective
studies are warranted to better evaluate the natural
course of renal AML, assess the risk factors for bleed-
ing, and compare the different treatment modalities.
AMLs that tend to bleed, even small AMLs, may have
different radiological and vasculature characteristics
[35]. Prospective patient series are needed to reliably
evaluate these aspects.
The results of this study may be affected by a number
of limitations that should be acknowledged. All studies
included in this study were of a retrospective nature
with limited follow-up. Data on major bleeding were
from non-consecutive, non-longitudinal studies, which
might have introduced a bias in the analysis of the
prevalence of this complication. Because embolisation
has been widely used as a prophylactic treatment of
AMLs since the 1990s, publications may be biased to-
ward reporting of complications and alternative surgical
treatment modalities.
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Conclusions
The present analysis showed that the prevalence of
major bleeding is significantly higher in AMLs larger
than 6 cm. Therefore, conservative treatment can be
considered for AMLs less than 6 cm in diameter,
whereas a threshold for invasive treatment of 4 cm may
not be appropriate. Among treatment methods, embol-
isation was associated with a significantly higher risk of
re-intervention. Further studies are needed to define risk
factors for bleeding and assess the relative benefits of
different treatment modalities.
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